Atlas Molecular Pharma Limited

Based in Bizkaia, Spain, and founded in 2015 by Óscar Millet, Atlas Molecular Pharma, a Spin-off of the CIC-Biogune research center, operates as a pharmaceutical research and development company that for the treatment of rare and ultra-rare metabolic diseases. In January 2026, Atlas Molecular Pharma raised EUR 5. 5 million in equity and grant funding led by Inveready Asset Management, with participation Center for Technological & Industrial Development, Kereon Partners, Gestion de Capital Riesgo del Pais Vasco, Endometrial DIDI, CRB Inverbio. Susana Castel is the current CEO of the company.

The firm develops its proprietary technology called Chassys ™ which is an NMR-based technology that develops therapies to correct the phenotype for a range of rare diseases. The firm offers disease-specific pharmacological chaperones for diseases like congenital erythropoietic porphyria, prion diseases, and tyrosinemia type I. Atlas Molecular Pharma primarily generates potential revenue through licensing agreements, milestone payments, and future royalties from partnered drug programmes. As a clinical‑stage biotechnology company, it also relies on equity financing and non‑dilutive grants to support ongoing R&D activities.

The company will use the January 2026 funding to advance the clinical development of ATL‑001 through a Phase I‑II trial.